Edition:
United States

OncoGenex Pharmaceuticals Inc (OGXI.OQ)

OGXI.OQ on NASDAQ Stock Exchange Capital Market

0.57USD
26 Aug 2016
Change (% chg)

-- (--)
Prev Close
$0.57
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
61,343
52-wk High
$3.37
52-wk Low
$0.46

Latest Key Developments (Source: Significant Developments)

Oncogenex's Phase 3 trial of Custirsen in men did not meet primary endpoint
Tuesday, 16 Aug 2016 07:00am EDT 

Oncogenex Pharmaceuticals Inc : Oncogenex announces results from the phase 3 affinity trial of custirsen in men with metastatic castrate-resistant prostate cancer . To initiate discussions with U.S. Food and drug administration to evaluate options related to an early analysis of phase 3 enspirit trial . Trial did not meet primary endpoint . Adverse events were consistent with those observed in previous trials of custirsen in metastatic crpc .Engaged MTS Health Partners, Lp as its advisor to assist with exploration of strategic alternatives.  Full Article

Oncogenex Pharma Q2 revenue $2.1 million vs est $1.2 million
Thursday, 4 Aug 2016 04:01pm EDT 

Oncogenex Pharmaceuticals Inc : Oncogenex pharmaceuticals, inc. Reports financial results for second quarter 2016 . Q2 revenue $2.1 million .Q2 revenue view $1.2 million -- Thomson Reuters I/B/E/S.  Full Article

Oncogenex Pharmaceuticals qtrly loss per share $0.12
Thursday, 12 May 2016 04:15pm EDT 

Oncogenex Pharmaceuticals Inc : Qtrly loss per share $0.12 . Oncogenex pharmaceuticals, inc. Reports financial results for first quarter 2016 . Q1 revenue $2.9 million .Q1 revenue view $4.1 million -- Thomson Reuters I/B/E/S.  Full Article

OncoGenex Pharmaceuticals Inc Presents Additional Phase 3 SYNERGY Analyses Showing Custirsen Significantly Reduced Serum Clusterin Levels in Metastatic Prostate Cancer Patients
Monday, 28 Sep 2015 01:00am EDT 

OncoGenex Pharmaceuticals Inc:Press release - OncoGenex presents additional phase 3 synergy analyses showing custirsen significantly reduced serum clusterin levels in metastatic prostate cancer patients; low levels correlate with improved survival in those at increased risk for poor o.Working closely with investigators and regulatory agencies to determine next steps as we collect more evidence of apatorsen's activity.Completion of enrollment in the phase 2 borealis-2 bladder cancer trial is expected to occur by the end of 2015.Custirsen has fast track designation by the U.S. food and drug administration for metastatic crpc and non-small cell lung cancer.  Full Article

OncoGenex announces phase 2 rainier results in previously untreated metastatic pancreatic cancer
Wednesday, 23 Sep 2015 07:00am EDT 

OncoGenex Pharmaceuticals Inc:Announces initial results from the Phase 2 Rainier(tm) study evaluating apatorsen in combination with ABRAXANE and gemcitabine compared to ABRAXANE and gemcitabine alone in patients with untreated metastatic pancreatic cancer.Says the addition of apatorsen to ABRAXANE and gemcitabine did not demonstrate a survival benefit compared to ABRAXANE and gemcitabine alone.Says the study was sponsored and conducted by Sarah Cannon Research Institute (SCRI) and further results will be presented by SCRI at a future medical meeting.  Full Article

FDA agrees with Oncogenex Pharmaceuticals Inc' phase 3 affinity protocol amendment
Wednesday, 10 Jun 2015 07:00am EDT 

Oncogenex Pharmaceuticals Inc:FDA agrees with oncogenex' phase 3 affinity protocol amendment.Says co-primary survival endpoint included for a prospectively-defined poor prognosis subpopulation.FDA agreed to the company's proposed amendment to the phase 3 affinity protocol and statistical analysis plan.Initiated review with European medicines agency for amendment to phase 3 affinity protocol,statistical analysis plan.Co,fda agreed interim analysis will occur for itt population when final analysis for the poor prognosis subpopulation occurs.Expects to have completed review with European medicines agency in the second half of 2015.  Full Article

OncoGenex Pharmaceuticals Inc gives data from borealis-1(TM) trial showing clinical benefit with apatorsen in metastatic bladder cancer
Monday, 1 Jun 2015 10:45am EDT 

OncoGenex Pharmaceuticals Inc:Says overall treatment was well tolerated.  Full Article

OncoGenex Pharmaceuticals announces share repurchase
Thursday, 30 Apr 2015 08:37am EDT 

OncoGenex Pharmaceuticals, Inc:Announced share purchase agreement with Lincoln Park Capital Fund, LLC.To sell up to $16 million of shares of common stock over 24-month term.Agreement includes an initial purchase of 956,938 series a-1 units.Says to use net proceeds from offering to advance proprietary product candidates custirsen and apatorsen.  Full Article

OncoGenex Pharmaceuticals Inc regains rights to Custirsen from Teva Technologies Inc
Monday, 27 Apr 2015 06:30am EDT 

OncoGenex Pharmaceuticals Inc:Says its wholly owned subsidiary, OncoGenex Technologies Inc., executed termination agreement with Teva Pharmaceuticals Ltd.Under which OncoGenex will regain rights to custirsen, an investigational compound currently in Phase 3 clinical development as a treatment for prostate and lung cancers.Says this transfer of rights occurs in connection with termination of the 2009 collaboration agreement between OncoGenex and Teva.Agreement between the two parties to terminate the collaboration includes a $23.2 mln payment from Teva.  Full Article

OncoGenex seeks strategic alternatives after drug study fails

OncoGenex Pharmaceuticals Inc said it was exploring strategic alternatives after its experimental drug failed to show survival benefit in a late-stage study in patients with advanced prostate cancer.